20 August 2026 — A personalised mRNA cancer vaccine developed by Moderna and Merck (MSD) has reportedly kept melanoma from returning in a Phase 3 clinical trial, marking the first time an individualised neoantigen therapy has demonstrated a statistically significant benefit in a late-stage randomised study. The combination of intismeran autogene (also known as V940 or mRNA-4157) with the immunotherapy drug pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB–IV melanoma.
The INTerpath-001 Trial
The Phase 3 INTerpath-001 trial enrolled over 1,100 patients with stage IIB, III, or IV melanoma — a range spanning from sizeable tumours confined to one site to disease that has spread to other parts of the body. Participants were randomly assigned to receive either the combination of intismeran and pembrolizumab, or pembrolizumab alone, for roughly a year following surgical resection.
Detailed results have not yet been peer reviewed or published. The two companies behind the vaccine — Moderna and Merck — announced the top-line findings in August 2026. It remains unclear how long the benefit from the vaccine lasts, and full data presentation is expected at an upcoming medical conference.
Building on Earlier Evidence
The Phase 3 success builds on earlier positive data from the Phase 2b KEYNOTE-942 trial. In June 2026, MSD and Moderna presented five-year results from that mid-stage trial of 157 patients at the American Society of Clinical Oncology (ASCO) annual meeting, reporting that the vaccine and drug together halved the risk of melanoma returning compared with the drug alone. Those findings were published in the Journal of Clinical Oncology.
How the Personalised Vaccine Works
These vaccines are unique to each person receiving them, built from the patient's own tumour:
- Tumour sequencing: A fragment of the patient's tumour is removed and its genetic code is read to pinpoint the specific mutations carried by that cancer.
- Neoantigen identification: Those mutations produce proteins known as neoantigens, which the immune system is capable of recognising as foreign but which typically go unnoticed.
- mRNA vaccine construction: Moderna's manufacturing process builds an mRNA vaccine carrying the genetic code for as many as 34 of those neoantigens, tailored to that individual patient.
- Immune training: Once injected, the vaccine teaches the immune system to recognise and attack any remaining cancer cells bearing those neoantigens.
Pembrolizumab (Keytruda) acts as the complementary agent: it dismantles the molecular camouflage that tumours use to escape immune detection. Cancer cells display a protein (PD-L1) that switches off approaching immune cells, and pembrolizumab blocks that signal so those cells remain active and can attack the tumour.
Expert Reactions
"This is certainly good news for patients with melanoma, but the study has much wider implications. It provides proof of principle that personalised cancer vaccines work. It is the first Phase 3 study that shows that a vaccine can protect against recurrences of one of the deadliest cancer types." — Prof Marco Gerlinger, Professor of Gastrointestinal Cancer Medicine and Consultant Medical Oncologist, Barts Cancer Institute, St Bartholomew's Hospital
"Personalised cancer vaccines are a fundamentally different way of thinking about cancer treatment. This is an important moment for a field that scientists have been working towards for many years. Within six years of the pandemic, we have mRNA vaccines to treat cancer." — Dr Lennard Lee, Consultant Medical Oncologist, Associate Professor and Senior National Clinical Adviser on Cancer Vaccines, University of Oxford
Early Signals in Pancreatic Cancer
The melanoma results come alongside early signals from other personalised mRNA cancer vaccine programmes. Earlier in 2026, the same mRNA technology produced long-lived immune responses against pancreatic cancer — a disease that kills roughly seven in eight patients within five years and has repeatedly defeated immunotherapy.
A Phase 1 trial of autogene cevumeran, a vaccine from BioNTech and Genentech led by Vinod Balachandran at Memorial Sloan Kettering Cancer Center, enrolled 16 patients who received chemotherapy, an immunotherapy drug, and a vaccine carrying up to 20 neoantigens drawn from their own tumours.
Follow-up figures presented at the American Association for Cancer Research meeting in 2026 showed that of the eight patients whose immune systems responded to the vaccine, seven were alive between four and six years after surgery. Of the eight non-responders, six had died, with a median survival of 3.4 years. Among responders, the tumour-killing T cells generated by the vaccine were still circulating six years later.
Broader mRNA Landscape
The cancer vaccine success coincides with a broader maturation of mRNA technology. A major review published in The Lancet in July 2026 analysed data from billions of mRNA vaccine doses administered between 2020 and 2025, concluding that the mRNA platform is fundamentally safe. The review noted that this clinical validation on a global scale has accelerated the use of mRNA technology in oncology, with approximately 11% of all mRNA clinical trials now targeting tumours.
Sources
- Gavi VaccinesWork: Cancer breakthrough as personalised mRNA vaccine stops melanoma returning, 20 August 2026.
- Pharmaphorum: MSD/Moderna skin cancer vaccine scores historic Phase 3 win.
- Cure Today: The first-ever personalised cancer vaccine to pass a Phase 3 trial.
- ecancer: ASCO 2026 — Cancer vaccine sustains 49% melanoma reduction after 5 years.
- Science Media Centre: Expert reaction to top-line results from the Phase 3 INTerpath-001 trial.
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
